The pharmaceutical industry’s traditional hierarchy continues to face dynamic shifts among the leaders. While Merck ($63.9B) and Pfizer ($62.5B) hold the top spots, double-digit growth from AstraZeneca (~18%), Eli Lilly (~34%), Novo Nordisk (~26%), and Amgen (~18%) signals an accelerating transformation in the sector’s competitive landscape. The continued strength of the GLP-1 market continues to…